RORA and diabetes mellitus: We then evaluated oxidative stress, and the results showed that maternal diabetes (STZ/VEH) significantly increased ROS formation (see Fig. 4d) and 3-nitrotyrosin formation (see Fig. 4e), respectively, compared to the CTL/VEH group (P < 0.0001); STZ/MnTBAP treatment completely, while RORA agonist (STZ/SR1078) partly, reversed this effect.